IL316075A - Crystalline form of lenifranor - Google Patents
Crystalline form of lenifranorInfo
- Publication number
- IL316075A IL316075A IL316075A IL31607524A IL316075A IL 316075 A IL316075 A IL 316075A IL 316075 A IL316075 A IL 316075A IL 31607524 A IL31607524 A IL 31607524A IL 316075 A IL316075 A IL 316075A
- Authority
- IL
- Israel
- Prior art keywords
- lanifibranor
- crystalline form
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305456 | 2022-04-05 | ||
| PCT/EP2023/058743 WO2023194339A1 (en) | 2022-04-05 | 2023-04-04 | Crystalline form of lanifibranor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316075A true IL316075A (en) | 2024-12-01 |
Family
ID=81326293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316075A IL316075A (en) | 2022-04-05 | 2023-04-04 | Crystalline form of lenifranor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250243192A1 (https=) |
| EP (1) | EP4504725A1 (https=) |
| JP (1) | JP2025511847A (https=) |
| KR (1) | KR20250002337A (https=) |
| CN (1) | CN119301120A (https=) |
| AR (1) | AR128985A1 (https=) |
| AU (1) | AU2023250118A1 (https=) |
| CA (1) | CA3247273A1 (https=) |
| IL (1) | IL316075A (https=) |
| MX (1) | MX2024012348A (https=) |
| PY (1) | PY2324870A (https=) |
| TW (1) | TW202404966A (https=) |
| UY (1) | UY40216A (https=) |
| WO (1) | WO2023194339A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240047402A (ko) * | 2021-08-12 | 2024-04-12 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도 |
| CN120857930A (zh) | 2023-01-19 | 2025-10-28 | 伊文蒂瓦公司 | 拉尼兰诺制剂 |
| KR20260020956A (ko) | 2023-06-05 | 2026-02-12 | 엥방티바 | 간 질환을 가진 환자의 내장 혈관 확장증의 치료에 사용하기 위한 라니피브라노르 |
| WO2025061927A1 (en) * | 2023-09-22 | 2025-03-27 | Inventiva | Method of making lanifibranor |
| WO2025132989A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025132955A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| TW202543596A (zh) | 2024-03-15 | 2025-11-16 | 法商因文帝華公司 | 預防接受過氧化物酶體增生劑活化受體（ppar）促效劑治療患者之血液病症 |
| WO2025191292A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Methods and monitoring of treatment with lanifibranor |
| WO2025238200A1 (en) | 2024-05-17 | 2025-11-20 | Inventiva | Treatment of a liver disease in patients with hepatic impairment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| WO2022122014A1 (zh) | 2020-12-11 | 2022-06-16 | 苏州科睿思制药有限公司 | Lanifibranor的晶型及其制备方法和用途 |
| WO2022143479A1 (zh) | 2020-12-29 | 2022-07-07 | 广东东阳光药业有限公司 | 一种化合物的固体形式及其制备方法和用途 |
| WO2022261410A1 (en) | 2021-06-10 | 2022-12-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of lanifibranor and process for preparation thereof |
| CN115466252A (zh) | 2021-06-11 | 2022-12-13 | 上海希迈医药科技有限公司 | 一种Lanifibranor的晶型及其制备方法 |
| KR20240047402A (ko) | 2021-08-12 | 2024-04-12 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도 |
-
2023
- 2023-03-31 TW TW112112450A patent/TW202404966A/zh unknown
- 2023-04-04 WO PCT/EP2023/058743 patent/WO2023194339A1/en not_active Ceased
- 2023-04-04 PY PY202302324870A patent/PY2324870A/es unknown
- 2023-04-04 IL IL316075A patent/IL316075A/en unknown
- 2023-04-04 JP JP2024559386A patent/JP2025511847A/ja active Pending
- 2023-04-04 CA CA3247273A patent/CA3247273A1/en active Pending
- 2023-04-04 CN CN202380042246.2A patent/CN119301120A/zh active Pending
- 2023-04-04 AR ARP230100832A patent/AR128985A1/es unknown
- 2023-04-04 EP EP23717474.3A patent/EP4504725A1/en active Pending
- 2023-04-04 AU AU2023250118A patent/AU2023250118A1/en active Pending
- 2023-04-04 US US18/854,287 patent/US20250243192A1/en active Pending
- 2023-04-04 KR KR1020247036771A patent/KR20250002337A/ko active Pending
- 2023-04-10 UY UY0001040216A patent/UY40216A/es unknown
-
2024
- 2024-10-04 MX MX2024012348A patent/MX2024012348A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023250118A1 (en) | 2024-10-17 |
| JP2025511847A (ja) | 2025-04-16 |
| KR20250002337A (ko) | 2025-01-07 |
| WO2023194339A1 (en) | 2023-10-12 |
| TW202404966A (zh) | 2024-02-01 |
| AR128985A1 (es) | 2024-07-03 |
| EP4504725A1 (en) | 2025-02-12 |
| CN119301120A (zh) | 2025-01-10 |
| MX2024012348A (es) | 2024-11-08 |
| PY2324870A (es) | 2023-10-27 |
| CA3247273A1 (en) | 2023-10-12 |
| UY40216A (es) | 2023-10-31 |
| US20250243192A1 (en) | 2025-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL316075A (en) | Crystalline form of lenifranor | |
| IL315411A (en) | Pure forms of crystalline eticarpant | |
| HUE067428T2 (hu) | 5-MEO-DMT kristályos hidrobromidsója | |
| GB202204778D0 (en) | Novel crystalline salt forms of mesembrine | |
| GB202102360D0 (en) | Crystalline compound | |
| IL304159A (en) | A preparation containing bl-8040 | |
| GB202411655D0 (en) | Application of circHIF1a | |
| AU2024314489A1 (en) | Crystalline salts of linsitinib | |
| SG11202108905UA (en) | Crystalline form of an avibactam derivative | |
| IL321171A (en) | Crystalline forms of 2-oxoquinazoline | |
| IL325727A (en) | Crystalline form | |
| LT4615820T (lt) | Kristalinės evenamido formos | |
| GB202014196D0 (en) | Crystalline form III of tetraacetylethylenediamine | |
| IL304683A (en) | Crystalline form of a piperazinyl-thiazole derivative | |
| GB202009218D0 (en) | Crystalline forms of entrectinib | |
| GB202002054D0 (en) | Crystalline forms of entrectinib | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| HK40116601A (en) | Crystalline form of lanifibranor | |
| EP4121434A4 (en) | CRYSTALLINE FORMS OF SQUALAMINE | |
| HK40096047A (en) | Crystalline form of aspacytarabine | |
| HK40082031A (en) | Crystalline form of lnp023 | |
| HK40111295A (en) | Crystalline forms of trofinetide | |
| CA3288524A1 (en) | Crystalline forms of evenamide | |
| GB202314050D0 (en) | Novel form of bemcentinib | |
| GB202316444D0 (en) | Salts of opicapone |